Hi-Tech Pharmacal (Nasdaq: HITK) reported earnings on July 9. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended April 30 (Q4), Hi-Tech Pharmacal whiffed on revenues and whiffed on earnings per share.

Compared to the prior-year quarter, revenue shrank. Non-GAAP earnings per share dropped significantly. GAAP earnings per share dropped to a loss.

Margins dropped across the board.

Revenue details
 Hi-Tech Pharmacal tallied revenue of $58.5 million. The four analysts polled by S&P Capital IQ foresaw revenue of $66.3 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.50. The four earnings estimates compiled by S&P Capital IQ anticipated $0.63 per share. Non-GAAP EPS of $0.50 for Q4 were 32% lower than the prior-year quarter's $0.73 per share. GAAP EPS were -$0.34 for Q4 compared to $0.72 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 46.7%, 520 basis points worse than the prior-year quarter. Operating margin was 12.9%, 880 basis points worse than the prior-year quarter. Net margin was -7.9%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $57.8 million. On the bottom line, the average EPS estimate is $0.44.

Next year's average estimate for revenue is $247.5 million. The average EPS estimate is $2.28.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 202 members out of 217 rating the stock outperform, and 15 members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 47 give Hi-Tech Pharmacal a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hi-Tech Pharmacal is outperform, with an average price target of $38.67.